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Abstract
Bacteriophages could be used along with burn wound care products to enhance antimicro-
bial pressure during treatment. However, some of the components of the topical antimicrobi-
als that are traditionally used for the prevention and treatment of burn wound infection might
affect the activity of phages. Therefore, it is imperative to determine the counteraction of
therapeutic phage preparations by burn wound care products before application in patients.
Five phages, representatives of two morphological families (Myoviridae and Podoviridae)
and active against 3 common bacterial burn wound pathogens (Acinetobacter baumannii,
Pseudomonas aeruginosa and Staphylococcus aureus) were tested against 13 different
products commonly used in the treatment of burn wounds. The inactivation of the phages
was quite variable for different phages and different products. Majority of the anti-infective
products affected phage activity negatively either immediately or in the course of time,
although impact was not always significant. Products with high acidity had the most adverse
effect on phages. Our findings demonstrate that during combined treatment the choice of
phages and wound care products must be carefully defined in advance.
Introduction
Almost all victims of burns have a more or less severe damage to the skin. The skin is our larg-
est organ and is vital in the host’s protection against infection. In addition, the depression of
immune responses induced by severe burns predisposes burn patients to infectious complica-
tions. Immediately after the accident, the burn will usually show little or no growth of microor-
ganisms as a consequence of the thermal insult, but in the first days after the burn, wounds
usually become colonized with gram-positive bacteria such as commensal skin staphylococci,
which are located deep within sweat glands and hair follicles and survived the thermal injury.
After an average of 5–7 days, gram-negative bacteria and yeasts, mostly from the host’s normal
gastrointestinal and upper respiratory microflora and/or from the hospital environment, also
colonize the burn wounds [1].
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The introduction of penicillin G in the 1950s resulted in the introduction of Staphylococcus
aureus as the major cause of infection in burn wound patients. Today, S. aureus remains a
common cause of early burn wound infection, but Pseudomonas aeruginosa from the patient’s
gastrointestinal tract and/or the hospital environment has become the most common burn
wound pathogen [2]. The incidence of infections due to other inherently antimicrobial resis-
tant gram-negative bacteria, such as Acinetobacter baumannii, Enterobacter spp. and Klebsiella
pneumoniae and of fungi has also increased in past decades. Due to their capacity for long-
term survival in the hospital environment, combined with a formidable inherent and acquired
antibiotic resistance, some A. baumannii strains have emerged as important nosocomial path-
ogens, especially in critically ill patients, as found in intensive care units and burn wound cen-
ters [3]. Multidrug resistant strains of A. baumannii, referred to as ‘Iraqibacter’ due to their
emergence in military treatment facilities during the Iraq War, have spread to civilian hospitals
due to the transfer of infected soldiers [4].
Colonization and infection of the burn wound by microorganisms can have disastrous con-
sequences. The presence of bacteria such as P. aeruginosa can seriously hamper skin graft take
[5] and, even though modern medical care has significantly reduced the mortality among ther-
mally injured patients, most deaths in severely burn-injured patients are due to burn wound
sepsis [1]. Different topical burn wound care products and techniques, such as silver and
iodine-containing creams, whether or not in combination with systemic antibiotics, have been
developed to prevent colonization and infection. However, these treatment methods are not
always effective, not least due to the increasing antimicrobial resistance in, amongst others,
burn wound pathogens. The introduction of new drugs and treatments against antimicrobial
resistant infections should be accelerated. One of the ‘new’ treatments that is increasingly con-
sidered is phage therapy [6–8], i.e. the use of bacterial viruses named bacteriophages (phages
for short) to treat bacterial infection. In recent years we designed phage cocktails for the treat-
ment of A. baumannii, P. aeruginosa and S. aureus infections in burn wound patients [9,10].
The most important limitation of phages is that they are host- or even strain-specific. Clini-
cians must first know which bacteria (or bacterial strains) are causing the infection before
treating the patient with phages. In addition, it was shown that burn wounds are often simulta-
neously colonized with different bacterial species (polymicrobial) and/or strains (polyclonal)
[11]. To prevent that a number of burn wound colonizing or infecting bacterial species or
strains would not be targeted, phage therapy would best be combined with conventional topi-
cal burn wound care products and where warranted with systemic antibiotics. In this context,
the therapeutic potential of phages for topical burn wound treatment will partly be determined
by their stability in burn wound care products. In the present study we determined the stability
of five therapeutically interesting phages against A. baumannii (Acibel004 and Acibel007), P.
aeruginosa (PNM and 14–1) and S. aureus (ISP) [9,10,12] in 13 common burn wound care
products (Bactroban, colistin milk, Flammazine, Flaminal Hydro and Flaminal Forte, Fucidin,
Furacin, Hibidil, Intrasite Gel, iso-Betadine Gel, P.O.H. (polymyxin-oxytetracyclene-hydro-
cortisone), Sulfamylon). These stability data are required for phages to be used within a burn
wound setting.
Materials and methods
Bacteriophages and bacterial strains
Five bacteriophages, i.e. A. baumannii phages Acibel004 and Acibel007, P. aeruginosa phages
PNM and 14–1 and S. aureus phage ISP were tested for their stability in different wound care
products. The phages ISP, PNM and 14–1 are components of a therapeutic bacteriophage
cocktail BFC1, previously developed [9]. The phages Acibel004 and Acibel007, active against
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A. baumannii, were previously isolated and characterized by our group [10]. All bacterio-
phages were propagated by the agar-overlay method [9] to the titer of 11 log pfu/ml and then
diluted in non-buffered physiological saline (0.9% NaCl) to the final titer of 9 log pfu/ml. Luria
Bertani (LB) broth and agar media (Becton Dickinson, Erembodegem, Belgium) were used for
propagation and culturing bacteria and phages. Characteristics of bacteriophages used in the
study are presented in Table 1.
Three bacterial strains were used in the study as host strains for propagation of the relevant
bacteriophages: A. baumannii 070517/0072 [10], P. aeruginosa 573 [9] and S. aureus ATCC
6538.
Burn wound care products and their active ingredients
In total, 13 different topical wound care products were used in the study. Detailed information
on the applied products is presented in Table 2. Bactroban, colistin milk, P.O.H. and Sulfamy-
lon cream were produced by the pharmacy department of the Queen Astrid Military Hospital
(QAMH). Flaminal Forte and Flaminal Hydro (Flen Pharma, Kontich, Belgium), Flammazine
1% (Sinclair Pharmaceuticals, Godalming, UK), Fucidin (Leo Pharma, Lier, Belgium), Furacin
(Limacom nv-Pharma Division, Diepenbeek, Belgium), Hibidil (Regent Medical, Irlam, UK),
Intrasite Gel and Iruxol (TJ Smith & Nephew, Hull, UK), iso-Betadine Gel 10% (Meda
Pharma, Brussels, Belgium) were obtained from the pharmacy of the QAMH.
Five active ingredients of four wound care products (Bactroban, Hibidil, iso-Betadine Gel
and P.O.H.) were also tested (Table 2): mupirocin (Alfa Aesar, Massachusetts, U.S.), chlorhexi-
dine gluconate (MP Biomedicals, Illkrich, France), povidone-iodine (Acros Organics, New Jer-
sey, USA), oxytetracycline hydrochloridum (Sigma-Aldrich, Steinheim, Germany) and
polymyxin B (Fagron NV, Waregem, Belgium).
Stability assays
Products were mixed with each phage suspension (9.0 log pfu/ml) at a ratio of 1:1, volume per
volume (v/v) for products of liquid consistency (colistin milk, Hibidil and solutions of the five
selected active ingredients) or weight per volume (w/v) for the creams and ointments. The five
active ingredients were diluted in physiological saline (NaCl 0.9%) to the concentration at
which they are present in the wound care products.
Mixtures were further incubated at 37˚C for 2, 4 and 24 h, where after the phages were
quantified by the agar-overlay method [9]. As a control, prior to the stability experiments each
phage was checked for its stability in physiological solution at 37˚C for 24 h. Effective thera-
peutic titer (ETT) was defined as 7.0 log pfu/ml. For Bactroban ointment, colistin milk, Hibidil
Table 1. Characteristics of bacteriophages used in the stability study.
Phage Name ISP PNM 14–1 Acibel004 Acibel007
Host species S. aureus P. aeruginosa P. aeruginosa A. baumannii A. baumannii
Source of isolation Unknown River water Sewage water Sewage water Sewage water
Place of isolation Tbilisi, Georgia Tbilisi, Georgia Regensburg, Germany Ghent, Belgium Ghent, Belgium
Date of isolation 1920–30 1999 2000 2010 2010
Family/genus of Caudovirales Myoviridae Twortvirus Podoviridae Phikmvvirus Myoviridae Pbunavirus Myoviridae ND Podoviridae Phikmvvirus
Genome size (kbp) 138.3 42.4 66.2 99.7 42.7
Accession No. FR852584 NA NC_011703 KJ473422 KJ473423
NA, non-applicable; ND, not defined.
https://doi.org/10.1371/journal.pone.0182121.t001
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Fig 1. Stability of bacteriophages in burn wound care products. (A) ISP phage; (B) PNM phage; (C) 14–1 Phage; (D) Acibel004 phage; (E)
Acibel007 phage. The results are the mean values of three titrations. ETT: effective therapeutic titer (7.0 log pfu/ml). The wound care products
are depicted in declining order of their inhibition activity.
https://doi.org/10.1371/journal.pone.0182121.g001
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solution, iso-Betadine Gel, P.O.H., mupirocin, oxytetracycline hydrochloridum and povidone-
iodine the detection threshold (DT) of phage activity had to be defined as the lowest dilution
of the product or active ingredient, at which bacterial strains still form confluent growth loan
on Petri dishes with LB agar. Below the DT, the growth of host bacteria is too much affected by
the antimicrobial activity of the product to allow an adequate assessment of phage activity.
Each test was performed in triplicate and mean values were calculated.
Measurement of pH
For 7 products (Flaminal Forte, Flaminal Hydro, Flammazine, Fucidin, Furacin, Iruxol, iso-
Betadine Gel) pH values were taken from the certificates of analysis. For the remaining prod-
ucts and the 5 selected active ingredients, pH values were tested by pH-meter HACH series
HQ40d with INTELLICALTM PHC101 electrode at 26˚C in triplicate, mean values and stan-
dard deviations were calculated.
Results and discussion
We previously developed a well-defined phage cocktail active against P. aeruginosa and S.
aureus [9] and applied it in a small pilot clinical trial in burn wound patients [13]. Several hur-
dles and pitfalls were encountered during this study, which hampered an adequate evaluation
of the efficacy of the phage cocktail. Nevertheless, the perspectives of phage therapy in burn
wound treatment are regarded as promising, especially in the light of the increasing number of
drug-resistant infections in this type of patients [1,14].
Because burn wounds are most often colonized or even infected by multiple bacterial species
or strains, it is likely that most of the future phage therapy and clinical trial protocols will pro-
vide for the simultaneous use of phage preparations and conventional topical antimicrobials.
Table 3. pH values of wound care products and their active ingredients.
Wound care
product
pH of
WCP
Active ingredient Concentration of AI (%) in
product
pH of AI
Bactroban 5.9±0.04 Mupirocin 2 3.8
±0.02
Colistin milk 3.5±0.02 NT NA NA
Flaminal Forte 5.8 NT NA NA
Flaminal Hydro 5.8 NT NA NA
Flammazine 5.5–5.8 NT NA NA
Fucidin 5.2 NT NA NA
Furacin 5.9 NT NA NA
Hibidil 7.2±0.02 Chlorhexidine gluconate 0.05 6.2
Intrasite Gel 6.4±0.02 NT NA NA
Iruxol 7.5 NT NA NA
iso-Betadine Gel 2.9 Povidone-iodine 10 2.1
±0.02
P.O.H. 4.7±0.02 Oxytetracycline
hydrochloridum
0.5 2.8
±0.03
Polymyxin B 0.12 5.8
±0.07
Sulfamylon 5.9±0.08 NT NA NA
NT, not tested; NA, non-applicable; WCP, wound care product; AI, active ingredient.
https://doi.org/10.1371/journal.pone.0182121.t003
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Moreover, current conventional burn wound care protocols imply the application of different
agents that ensure hydration and debridement in addition to an antimicrobial activity.
Phages will probably always be used in conjunction with several other medical approaches
in burn wound care, and therefore, it is important to determine the stability of phages in the
presence of other care products.
A broad variety of creams and ointments containing natural and synthetic antibiotics or
anti-infective agents are available. Hydration and subsequent debridement of the wounds are
often provided by hydrogels. A high variety of hydrogels is available on the pharmaceutical
market and some of them (e.g. Flaminal Hydro) also exhibit antimicrobial properties. Some
antimicrobial topicals may also contain also corticosteroids conferring an anti-inflammatory
effect.
In the present study we included a large variety of burn wound care products, including
hydrogels.
Because it is generally accepted that therapeutic phage preparations should contain active
phage particles in concentrations of 6.0–7.0 log pfu/ml [15], we considered 7.0 log pfu/ml as
an effective therapeutic titre (ETT). ETT is recommended to be present in therapeutic phage
cocktails after incubation with the wound care products.
Four topical wound care products used in this study, i.e. Bactroban ointment, colistin milk,
Fucidin cream and P.O.H. ointment, contain antibiotics produced by different microorgan-
isms as the main active component along with other additives, including steroids. Each of
these products had variable activity on the tested phages.
Bactroban cream contains 2% mupirocin, a bacteriostatic antibiotic of the monoxycarbolic
acid class, produced by Pseudomonas fluorescens. The mechanism of its activity implies block-
ing the integration of isoleucine into the peptide during synthesis via mimicking the epoxy
moiety of monic acid and isoleucine tRNA synthetase [16–19]. Mupirocin has good activity
against gram-positive cocci and mycoplasmas. Although mupirocin lacks the ability to pene-
trate the cell wall of gram-negative bacilli, it is still active against some gram-negative cocci
and coccobacilli, such as Bordetella pertussis, Haemophilus influenzae, Moraxella catarrhalis,
and Pasteurella multocida [19].
Bactroban affected the activity of phages already after 2 hours of incubation, causing a grad-
ual decrease in activity with complete inactivation (or activity below the DT) for all phages
after 4 hours, except for myovirus 14–1, which maintained activity above the ETT even after
24 hours of incubation (Fig 1, S1 Fig). Bactroban’s active ingredient mupirocin, tested sepa-
rately at the concentration of 2%, showed a higher inactivation degree than the final product.
All phages, except 14–1, were inactivated below the ETT already after 2 hours of incubation.
Only phage 14–1 maintained its activity above the ETT even after 24 hours, similar to Bactro-
ban. The higher inactivation degree of mupirocin could be due to its much lower pH value
(3.8) in comparison to Bactroban (5.9) (Table 3).
Colistin milk contains Polymyxin E as its active component. Polymyxin E is a multicompo-
nent polypeptide antibiotic and comprises of polymyxins A and B. Polymyxins are active
against the majority of gram-negative bacteria with some exceptions such as the genera Neis-
seria, Proteus and Serratia, which are inherently resistant [20]. Polymyxin E has comparable
detergent-like mechanism of action on the outer-membrane of gram-negative bacteria [20–
22]. All phages, except myovirus 14–1, got inactivated immediately after getting into contact
with colistin milk, with activity dropping below the detection level already after 2 hours,
whereas phage 14–1 got inactivated only after 24 hours.
Fucidin contains fusidic acid as its active component, along with hydrocortisone acetate.
Fusidic acid is considered as a bacteriostatic antibiotic with relatively narrow antibacterial
spectrum, mostly active against gram-positive bacteria and exhibiting good in vitro activity
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against Mycobacterium tuberculosis as well [23,24]. Fusidic acid acts as an inhibitor of bacterial
protein synthesis by preventing the turnover of elongation factor G (EF-G) from the ribosome
[24]. Fucidin barely inactivated phages, whereby the activity of only two of them, i.e. myovirus
ISP and podovirus Acibel007, decreased below the ETT titer after 24 hours of incubation (Fig
1, S1 Fig).
P.O.H., also well-known as terra-cortril ointment (Table 2), contains the two antibiotics
oxytetracycline hydrochloridum and polymyxin B along with hydrocortisone acetate. Oxytet-
racycline is a broad-spectrum antibiotic used to treat various kinds of infections. It inhibits
translation in bacterial cells by binding to the 30S ribosomal subunit and as such preventing
the amino-acyl-tRNA from binding to the A site of the ribosome [25]. As other polymyxins,
polymyxin B sulfate acts as a cationic detergent on the bacterial cell wall of gram-negative bac-
teria, interacting with the lipopolysaccharides of the outer membrane, affecting membrane
permeability and causing cell death eventually. Hydrocortisone is a representative of mild cor-
ticosteroids and is widely used to treat a broad variety of inflammatory skin disorders [26].
Phages were affected by P.O.H. immediately after incubation, and activity of almost all
phages dropped below the DT after 2 hours. The only exception was myovirus 14–1, whose
activity decreased gradually and dropped below the DT only after 24 hours (Fig 1, S1 Fig).
Two active ingredients of P.O.H., such as oxytetracycline hydrochloridum and polymyxin B
were tested separately. Phages were affected differently by these ingredients. Polymyxin B had
almost no effect on any of the tested phages, with the exception of ISP, whose activity dropped
below the ETT after 24 hours. While oxytetracycline reduced the activity of most of the phages
below the ETT immediately or after 2 hours, with the exception of 14–1, which was only inacti-
vated after 4 hours of incubation (S1 Fig). Interestingly, the oxytetracycline solution exhibited
an extremely low pH value (2.8) compared to that of the polymyxin B solution (5.8) (Table 3).
The differences in pH of between these two active ingredients of P.O.H. could be at the basis of
the observed differences in phage inactivation.
Flammazine and Sulfamylon creams contain silver sulfadiazine and mafenide as active
ingredients, respectively. Both compounds are representatives of sulfonamides, first widely
used synthetic antibiotics. Flammazine cream contains 1% of silver sulfadiazine as a main
ingredient and this has broad antimicrobial activity against gram- negative and gram-positive
bacteria as well as yeasts. The general mechanism of activity of sulfonamides is based on the
inhibition of the bacterial enzyme dihydropteroate synthetase involved in the folate pathway
[27]. Silver ions, in turn, are capable to inhibit microbial growth due to several mechanisms
such as protein and enzyme inactivation and the blocking of replication and transcription pro-
cesses by intercalating into DNA molecules [28,29]. However, exact mechanism of activity of
silver sulfadiazine has not yet been determined. It is assumed that the overall effect of this com-
pound is due to either the synergetic interaction of sulfadiazine and silver ions or separate
activity of each component. Unlike other silver salts, silver sulfadiazine while interacting with
sodium chloride containing body fluids (e.g. serum), releases silver ions slowly and sustainably
[30], which makes silver sulfadiazine highly effective in the treatment of long-healing wounds,
such as burn wounds.
The exact mechanism of mafenide acetate’s activity is also unknown, except that it differs
from that of other sulfonamides [27]. Mafenide is particularly effective for the treatment of
burn wounds because it is agent that most effectively penetrates the eschar, and is therefore
capable of suppressing dense bacterial proliferation beneath the eschar surface. Sulfamylon
cream contains 8.5% mafenide acetate, which exerts bacteriostatic action against both gram-
negative and gram-positive organisms and which is especially effective against P. aeruginosa
and Clostridium spp.
Phage stability and burn wound topicals
PLOS ONE | https://doi.org/10.1371/journal.pone.0182121 July 27, 2017 10 / 15
Phage activity was variably affected by Flammazine. P. aeruginosa phages either were
slightly affected or not affected at all. S. aureus phage ISP appeared to be especially sensitive
towards Flammazine and showed gradual decline in activity with a final 4.9 log decrease after
24 hours of incubation. The A. baumannii phages showed relative tolerance and their titer
decreased in the range of 1.3–2.6 log after 24 hours (Fig 1, S1 Fig).
Sulfamylon cream did not much affect phage activity and all phages maintained their activ-
ity even after 24 hours of incubation with the exception of the A. baumannii phages, Acibel004
and Acibel007, for which activity declined by 1.6–1.7 log after 24 hours (Fig 1, S1 Fig).
Another anti-infective topical that contains a synthetic antibiotic is Furacin 0.2%. Nitrofural
is the active ingredient of Furacin ointment and, next to being bactericidal it also expresses
anti-trypanosomal, anti-fungal activity and it is widely used in human and animal medicine.
Nitrofural inhibits several bacterial enzymes, especially those involved in the aerobic and
anaerobic degradation of glucose and pyruvate although the exact mechanism of action is
unknown [27,31]. Phage activity was not much affected by incubation in Furacin, and only the
A. baumannii phages Acibel004 and Acibel007 showed 2.0 and 0.7 log of decline in activity,
respectively after 24 hours of incubation, though the values didn’t drop below the ETT.
Two antiseptics have been tested in our study: Hibidil 0.05% and iso-Betadine Gel 10%.
The main component of the antiseptic Hibidil is chlorhexidine, which absorbs onto the micro-
organism’s cell wall and disrupts the integrity of the cell membrane, causing leakage of intra-
cellular components of the organisms [32]. Hibidil had weaker impact on phage activity than
iso-Betadine Gel. The gradual decline in phage activity started after 4 hours of incubation and
after 24 hours two phages 14–1 and Acibel004 still maintained activity above the ETT (Fig 1,
S1 Fig). The 0.05% chlorehexidine gluconate solution had a similar effect on phages as its final
product Hibidil (S1 Fig), even though their pH values differ (7.18 and 6.2, respectively) it must
be said that both pH values can be considered to represent a more or less neutral.
Iso-Betadine Gel contains the povidone-iodine complex from which free iodine is slowly
liberated, killing eukaryotic and prokaryotic cells through iodination of lipids and oxidation of
cytoplasmic and membrane compounds. As a rule, povidone-iodine exhibits a broad range of
microbicidal activity against bacteria, fungi, protozoa, and viruses [33]. Iso-Betadine 10% Gel
expressed its activity on bacteriophages immediately upon contact and no phage activity could
be detected in any samples (even at time zero), except for phage 14–1, which declined with 5.2
log immediately and also dropped below the DT after 2 hours. The 10% povidone-iodine solu-
tion also immediately inactivated all phages, with the exception of 14–1, which only dropped
below the DT after 2 hours (S1 Fig). Detection threshold values differed slightly between povi-
done-iodine and its final product iso-Betadine Gel (S1 Fig).
Flaminal Forte, Flaminal Hydro, Intrasite Gel and Iruxol are used for the debridement and
desloughing of burn wounds, although the active ingredients of each of them have different
modes of activity and in addition Flaminal Forte and Flaminal Hydro also have anti-bacterial
properties.
Flaminal Forte and Flaminal Hydro are hydrogels with enhanced wound debridement
activity due to the presence of alginate. In addition, the glucose oxidase-lactoperoxidase-guaia-
col (GLG) enzyme system confers antimicrobial activity to both products. The difference
between Flaminal Forte and Flaminal Hydro is in the concentration of alginate, respectively
5.5 and 3.5%. Phage activity was affected by Flaminal Hydro only after 24 h of incubation but
still stayed above the ETT. The decline varied between 1.3–1.9 log for all phages with exception
for 14–1, whose activity stayed stable at 9.0 log pfu/ml. The Flaminal Forte formulation had a
more pronounced effect on phage activity than Flaminal Hydro. Activity declined far below
the ETT after 24 h of incubation and the range of decline varied between 1.7–9.0 log, whereby
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only myovirus 14–1 maintained activity above the ETT with a final concentration of 8.0 log
pfu/ml (Fig 1, S1 Fig).
Intrasite Gel is an amorphous hydrogel which gently rehydrates necrotic tissue of the
wound facilitating autolytic debridement. Intrasite Gel is supposed to provide for an optimal
moist wound management environment. Intrasite Gel, like Iruxol, had no effect on phage
activity.
Iruxol, of which the main component is collagenase, which along with other proteases
digests all protein components of the wound thus ensuring chemical debridement, did not
affect the activity of any of the tested phages.
We considered the possible correlation between phage activity and pH of the wound care
products and a selection of their active ingredients. It is known from previous studies [34] that
optimal pH range for most of the representatives of Caudovirales active against common bacte-
rial pathogens is 5.0–9.0 [34]. As could be expected, the wound care products and the active
ingredients, which exhibited high acidity (below 5.0), i.e. colistin milk, iso-Betadine Gel, P.O.
H., mupirocin, oxytetracycline hydrochloride and povidone-iodine (Table 3), had a significant
negative impact on phage activity. The most resistant phage appeared to be myovirus 14–1,
which belongs to the genus Pbunavirus. Representatives of this genus are characterized by
acid-resistant capsids resulting in a pronounced resistance to acid environments [12].
Representatives of Twortvirus and Phikmvvirus genera, to which ISP, PNM and Acibel007
phages respectively belong, are not known to exhibit extraordinary resistance towards pro-
nounced acidic conditions [34–36]. This study confirms these observations.
Precise taxonomic affiliation of myovirus Acibel004 is not defined, most closely related
genus is Kpp10virus [10]. However, there is not much data available on biophysical stability of
representatives of this genus, which makes comparison difficult. Based on our study Acibel004
proved to be quite sensitive to low pH values too, though it is not the most sensitive one
among the five tested phages. Phages ISP and Acibel007 exhibit the least stability in most of
the experiments conducted during the study.
Conclusions
In conclusion, each of the burn wound care products expressed variable activity on the tested
phages. No correlation was detected between morphology, host range of phages and their sta-
bility towards the wound care products. The myovirus 14–1, active against P. aeruginosa
strains, appeared to be the most stable phage, of which the activity in most of the assays stayed
above the ETT during at least 4 hours of incubation, with iso-Betadine Gel as the only excep-
tion. The other four phages expressed variable but more or less similar tolerance towards all
tested products. Phages were mostly hampered by anti-infective products, such as Bactroban,
colistin milk, iso-Betadine and P.O.H. ointment. It should be noted that all wound care prod-
ucts have a complex composition, and that—besides the active components—they contain a
variable number of different additives, conferring stabilizing effects to the active components.
This makes it difficult to speculate which particular components of the tested products are
responsible for phage inactivation. Certain combinations of various ingredients might also
have inactivation effects. The results also suggest a correlation between the acidity of certain
burn wound products and phage inactivation. Before applying phage preparation along with
common burn wound care products careful stability/activity analysis should be carried out as
every phage expresses different levels of tolerance/resistance towards different products.
Simultaneous application of some products, especially of those with antiseptic activity and
high acidity, along with phages should be avoided. However phage preparations can still be
applied with most of the products and will stay active during at least 4 hours of incubation.
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Phages can absolutely be recommended to be applied with neutral hydrogels aimed for wound
debridement and not-containing any anti-infective agents. Nevertheless, the tests performed
in the scope of this study provide information only about in vitro activity and further in vivo
experiments or clinical trials are needed to prove efficacy of joint application of phage and
conventional therapy products in treatment of burn wounds.
Supporting information
S1 Fig. Stability of bacteriophages in burn wound care products and a selection of their
active ingredients (in alphabetical order). A) Burn wound care products; B) Active ingredi-
ents. The results are the mean values of three titrations. Standard deviations are indicated.
Detection thresholds for each product and each bacterial species are indicated by color gradi-
ent columns. ETT: effective therapeutic titer (7.0 log pfu/ml).
(PDF)
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